Abstract
Since MRD is the major cause for relapses of malignant diseases, strategies utilizing ITs to target tumor cells surviving conventional treatment have attracted scientific and clinical interest. Many different ITs against various blood-borne as well as solid malignancies have demonstrated specific potent anti-tumor effects in vitro and in animal models. Some of these have already undergone clinical phase I/II trials. The dose-limiting toxicities of RTA ITs include manifestation of VLS presenting as decreased urinary sodium excretion, hypoalbuminemia, fatigue, hypotonia, myalgia, pulmonary edema, or rhabdomyolysis. Problems encountered clinically include the development of HAMA, HARA, and HACA and the selection of antigen- deficient malignant clones. Most clinical trials performed with ITs so far were conducted in heavily pretreated patients presenting with high tumor burdens. Thus, the responses observed with ITs in these trials are very encouraging and warrant further exploration.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 13-33 |
| Number of pages | 21 |
| Journal | Current Topics in Microbiology and Immunology |
| Volume | 234 |
| State | Published - 1998 |
Fingerprint
ASJC Scopus subject areas
- Immunology and Allergy
- Microbiology (medical)
- Immunology and Microbiology(all)
- Microbiology
Cite this
The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. / Engert, A.; Sausville, E. A.; Vitetta, E.
In: Current Topics in Microbiology and Immunology, Vol. 234, 1998, p. 13-33.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma
AU - Engert, A.
AU - Sausville, E. A.
AU - Vitetta, E.
PY - 1998
Y1 - 1998
N2 - Since MRD is the major cause for relapses of malignant diseases, strategies utilizing ITs to target tumor cells surviving conventional treatment have attracted scientific and clinical interest. Many different ITs against various blood-borne as well as solid malignancies have demonstrated specific potent anti-tumor effects in vitro and in animal models. Some of these have already undergone clinical phase I/II trials. The dose-limiting toxicities of RTA ITs include manifestation of VLS presenting as decreased urinary sodium excretion, hypoalbuminemia, fatigue, hypotonia, myalgia, pulmonary edema, or rhabdomyolysis. Problems encountered clinically include the development of HAMA, HARA, and HACA and the selection of antigen- deficient malignant clones. Most clinical trials performed with ITs so far were conducted in heavily pretreated patients presenting with high tumor burdens. Thus, the responses observed with ITs in these trials are very encouraging and warrant further exploration.
AB - Since MRD is the major cause for relapses of malignant diseases, strategies utilizing ITs to target tumor cells surviving conventional treatment have attracted scientific and clinical interest. Many different ITs against various blood-borne as well as solid malignancies have demonstrated specific potent anti-tumor effects in vitro and in animal models. Some of these have already undergone clinical phase I/II trials. The dose-limiting toxicities of RTA ITs include manifestation of VLS presenting as decreased urinary sodium excretion, hypoalbuminemia, fatigue, hypotonia, myalgia, pulmonary edema, or rhabdomyolysis. Problems encountered clinically include the development of HAMA, HARA, and HACA and the selection of antigen- deficient malignant clones. Most clinical trials performed with ITs so far were conducted in heavily pretreated patients presenting with high tumor burdens. Thus, the responses observed with ITs in these trials are very encouraging and warrant further exploration.
UR - http://www.scopus.com/inward/record.url?scp=0031838566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031838566&partnerID=8YFLogxK
M3 - Article
VL - 234
SP - 13
EP - 33
JO - Current Topics in Microbiology and Immunology
JF - Current Topics in Microbiology and Immunology
SN - 0070-217X
ER -